METTL14 and acute myeloid leukemia: Considering that m6A modifications are relevant to cancer development and catalyzed predominately by the METTL3-METTL14 methyltransferase complex, a selective METTL3 inhibitor has recently been developed and exhibits a significant therapeutic effect in acute myeloid leukemia [56].